Company: PSTV
Filing Date: 2025-04-04
Form Type: S-3
Source: 0001193125-25-073481
Chunk: 13

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-04
Form: S-3
Chunk 13
---
 share combination event and
ending on the fifth (5) trading day immediately following such date is less than the exercise price of the Warrants then in effect, then the exercise price of the Warrants will be reduced to the
lowest daily volume weighted average price during such period (subject to a minimum exercise price of the Floor Price), and the number of shares issuable upon exercise will be proportionately adjusted such that the aggregate exercise price will
remain unchanged.

Warrant Stockholder Approval. Under Nasdaq listing rules, the Warrants may not be exercised unless and until we
obtain the approval of our stockholders (the “Warrant Stockholder Approval”). While we intend to promptly seek stockholder approval, there is no guarantee that the Warrant Stockholder Approval will ever be obtained. If we are unable to
obtain the Warrant Stockholder Approval, the Warrants may not be exercised and will have substantially less value. In addition, we will incur substantial cost, and management will devote substantial time and attention, in attempting to obtain the
Warrant Stockholder Approval.

5

SELLING STOCKHOLDERS The selling stockholders listed in the table below may from time to time offer and sell up to an aggregate of 1,565,044,860 shares of common stock offered and issued in the March PIPE Financing pursuant to this prospectus and the applicable prospectus supplements, which consists of:

| • |     | up to 3,077,270 shares of common stock; |

| • |     | up to 19,650,000 shares of common stock issuable upon exercise of 
 Pre-Funded Warrants;                                              |

| • |     | up to 280,421,380 shares of common stock that could become issuable upon exercise of Series A Common Stock 
 Warrants; and                                                                                              |

| • |     | up to 1,261,896,210 shares of common stock that could become issuable upon exercise of Series B Common Stock 
 Warrants.                                                                                                    |

The number of shares issuable upon the Common Warrants has been calculated assuming the exercise price of the Common Warrants has been reduced to the Floor Price as discussed under Private Placement above. The selling stockholders have not had any material relationship with us within the past three years, except for the ownership of our equity or debt securities. As used in this prospectus, the term “selling stockholders” includes the selling stockholders listed in the table below, together with any additional selling stockholders listed in a subsequent amendment